Legal Opinion
Novo Nordisk v. Caraco Pharmaceutical Laboratories, Ltd.
District Court, E.D. Michigan
Decided August 31, 2009No. Case 05-40188PublishedCited by 5 opinions
1Opinion of the Court
MEMORANDUM
AVERN COHN, District Judge.
This memorandum explains the reasons for denying plaintiffs’ motion (Doc. 337) to dismiss defendants’ Count IV of the Third Amended Answer and Counterclaim (Doc. 309) (for an order requiring correction of a “use code”), and to Strike Defendants’ Sixth Affirmative Defense (Doc. 309) (for an order requiring correction of a “use eode”) in an order entered on August 20, 2009 (Doc. 369). The order is not a decision on the merits. The order means only that the Counterclaim states a cognizable cause of action and that the Affirmative Defense states a cognizable…
2Cases cited5 opinions
- In Re Buspirone Patent LitigationDistrict Court, S.D. New York · 2002
- aaiPharma Inc. v. ThompsonCourt of Appeals for the Fourth Circuit · 2002
- Mylan Pharmaceuticals, Inc. v. ThompsonCourt of Appeals for the Federal Circuit · 2001
- Mylan Pharmaceuticals, Inc. v. ThompsonDistrict Court, District of Columbia · 2001
- Purepac Pharmaceutical Co. v. ThompsonDistrict Court, District of Columbia · 2002
3Cited by5 opinions
- Veloxis Pharmaceuticals, Inc. v. United States Food and Drug AdministrationDistrict Court, District of Columbia · 2015
- Novo Nordisk A/S v. Caraco Pharmaceutical Laboratories, Ltd.District Court, E.D. Michigan · 2011
- Novo Nordisk A/S v. Caraco Pharmaceutical Laboratories, Ltd.District Court, E.D. Michigan · 2009
- Novo Nordisk A/S v. Caraco Pharmaceutical Laboratories, Ltd.Court of Appeals for the Federal Circuit · 2010
- Novo Nordisk A/S v. Caraco Pharmaceutical Laboratories, Ltd.Court of Appeals for the Federal Circuit · 2010